Director or Officer Departures, Elections, Appointments, and Compensation Arrangements

Filing Overview

Registrant: Galecto, Inc. The request metadata identifies Damora Therapeutics, Inc., but the filing itself names Galecto, Inc. as the registrant. This Form 8-K reports an event dated June 30, 2021 and was signed July 6, 2021.

The company’s common stock traded on Nasdaq under the symbol GLTO. The filing reports adoption of a new Separation Benefits Plan and does not provide quarterly or annual financial results.

Key Financial Information

  • Revenue, profit, cash flow, and margins: The filing text does not provide clear values.
  • Debt and liquidity: The filing text does not provide clear values.
  • Potential financial obligations: The plan may require salary continuation, benefits payments, bonus payments, and accelerated equity vesting upon qualifying terminations. No aggregate cost or liability estimate is disclosed.

Material Changes and Executive Separation Benefits

On June 30, 2021, the Compensation Committee adopted a Separation Benefits Plan covering the CEO, CFO, Chief Medical Officer, Chief Operating Officer, General Counsel, certain other executive officers, and other employees designated by the Board.

  • For qualifying terminations outside a sale-event period, the company generally must continue base salary for 15 months for the CEO, 12 months for other C-level officers, or another period determined by the Board for other covered employees.
  • Eligible U.S. employees may receive company-paid shares of COBRA medical, dental, and vision premiums during the applicable severance period.
  • C-level officers may receive a prorated annual bonus, subject to applicable bonus criteria.
  • Time-based equity awards that would have vested during the severance period may vest upon termination.

Sale Event Provisions, Outlook, and Risks

  • For qualifying terminations in connection with a sale event or within the following 24 months, the CEO may receive a lump sum equal to 18 months of base salary; other C-level officers may receive 12 months; and other covered employees may receive nine months.
  • Sale-event benefits also include applicable insurance premiums, a target-bonus payment equal to 150% for the CEO, 100% for other C-level officers, or 75% for other covered employees, and full vesting of eligible time-based equity awards.
  • Benefits are conditioned on execution and effectiveness of a separation and release agreement.
  • Benefits may be reduced if necessary to avoid the Section 4999 excise tax, subject to the plan’s net-benefit comparison.
  • The Board may amend or terminate the plan, subject to specified approval, notice, employee-consent, and 24-month post-sale restrictions.
  • The filing provides no management revenue or earnings guidance. Unusual items consist of the potential severance, bonus, insurance, and equity-acceleration obligations.

Investor Verification Items

  • Verify the correct issuer, because the supplied metadata names Damora Therapeutics, Inc., while the filing names Galecto, Inc.
  • Review Exhibit 10.1 for the complete definitions of Cause, Good Reason, Sale Event, eligibility, and benefit conditions.
  • Assess the number of covered employees and the potential aggregate cash and equity cost of the plan.
  • Check subsequent filings for amendments to the plan, executive departures, a sale event, or recognition of related compensation expense.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.